SEATTLE, Jan. 31, 2017 -- Trupanion, Inc. (Nasdaq:TRUP), a leading provider of medical insurance for cats and dogs, announced today it will report financial results for its 2016 fourth quarter and full year after the market closes on Tuesday, February 14, 2017. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET.
A live webcast will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call.
Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available, one hour after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13652718.
About Trupanion:
Trupanion is a leading provider of medical insurance for cats and dogs throughout the United States and Canada. For almost two decades, Trupanion has given pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance. Trupanion is listed on the Nasdaq Stock Exchange under the symbol TRUP. The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. For more information please visit Trupanion.com.
Contacts: Investors: Tyler Drew, Addo Investor Relations 310.829.5400 [email protected] Media: Scott Janzen, Trupanion Director of Communications 888.612.1138 ext 3450 [email protected]


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Italy Fines Apple €98.6 Million Over App Store Dominance
FDA Approves Mitapivat for Anemia in Thalassemia Patients
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 



